Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LXRXNASDAQ:OMERNASDAQ:RNAZOTCMKTS:SEOVF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXRXLexicon Pharmaceuticals$0.660.0%$0.55$0.28▼$2.45$238.55M1.076.60 million shs3.19 million shsOMEROmeros$3.16-1.9%$6.55$2.97▼$13.60$184.25M2.42665,642 shs569,591 shsRNAZTransCode Therapeutics$6.97-8.5%$11.98$6.15▼$1,838.76$5.81M1.52100,387 shs63,917 shsSEOVFSernova$0.14-8.5%$0.14$0.10▼$0.29$47.50M1.2632,913 shs67,307 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXRXLexicon Pharmaceuticals-0.02%+23.30%-1.77%-7.06%-60.49%OMEROmeros-1.86%-1.56%-54.79%-65.58%-7.60%RNAZTransCode Therapeutics-8.53%-14.58%-20.72%-96.92%-99.98%SEOVFSernova-8.48%-3.60%-5.74%+0.63%-33.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLXRXLexicon Pharmaceuticals3.3382 of 5 stars4.24.00.00.02.71.70.6OMEROmeros3.9619 of 5 stars3.42.00.04.43.11.70.6RNAZTransCode Therapeutics2.6378 of 5 stars3.52.00.00.04.40.01.3SEOVFSernovaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLXRXLexicon Pharmaceuticals 2.40Hold$3.67455.64% UpsideOMEROmeros 2.80Moderate Buy$22.50612.03% UpsideRNAZTransCode Therapeutics 3.00Buy$280.003,917.22% UpsideSEOVFSernova 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SEOVF, LXRX, RNAZ, and OMER Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/13/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.005/7/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/16/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$560.00 ➝ $280.004/11/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/1/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/1/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/28/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/21/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/13/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$560.00 ➝ $560.003/7/2025LXRXLexicon PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $6.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLXRXLexicon Pharmaceuticals$31.21M7.64N/AN/A$0.38 per share1.74OMEROmerosN/AN/AN/AN/A($0.40) per shareN/ARNAZTransCode TherapeuticsN/AN/AN/AN/A$86.32 per shareN/ASEOVFSernovaN/AN/AN/AN/A($0.03) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLXRXLexicon Pharmaceuticals-$177.12M-$0.51N/AN/AN/A-4,109.41%-107.38%-64.09%8/7/2025 (Estimated)OMEROmeros-$117.81M-$2.65N/AN/AN/AN/AN/A-49.92%8/6/2025 (Estimated)RNAZTransCode Therapeutics-$18.55MN/A0.00N/AN/AN/A-649.03%-281.34%N/ASEOVFSernova-$23.65M-$0.05N/A∞N/AN/AN/A-283.67%6/12/2025 (Estimated)Latest SEOVF, LXRX, RNAZ, and OMER EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q4 2024RNAZTransCode Therapeutics-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A5/15/2025Q1 2025OMEROmeros-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A5/13/2025Q1 2025LXRXLexicon Pharmaceuticals-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million3/31/2025Q4 2024OMEROmeros-$0.71-$0.63+$0.08-$0.54$0.40 millionN/A3/14/2025Q1 2025SEOVFSernovaN/A-$0.01N/A-$0.01N/AN/A3/6/2025Q4 2024LXRXLexicon Pharmaceuticals-$0.11-$0.09+$0.02-$0.09$6.48 million$26.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ASEOVFSernovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLXRXLexicon Pharmaceuticals0.567.457.43OMEROmerosN/A2.962.96RNAZTransCode TherapeuticsN/A1.581.58SEOVFSernovaN/A0.320.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLXRXLexicon Pharmaceuticals74.70%OMEROmeros48.79%RNAZTransCode TherapeuticsN/ASEOVFSernovaN/AInsider OwnershipCompanyInsider OwnershipLXRXLexicon Pharmaceuticals4.50%OMEROmeros12.30%RNAZTransCode Therapeutics0.10%SEOVFSernovaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLXRXLexicon Pharmaceuticals140361.49 million229.49 millionOptionableOMEROmeros21058.31 million50.82 millionOptionableRNAZTransCode Therapeutics9833,000677,000Not OptionableSEOVFSernovaN/A328.49 millionN/ANot OptionableSEOVF, LXRX, RNAZ, and OMER HeadlinesRecent News About These CompaniesSernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 DiabetesMay 22 at 7:00 AM | globenewswire.comSernova (OTCMKTS:SEOVF) versus Eliem Therapeutics (NASDAQ:ELYM) Head to Head ReviewMay 20, 2025 | americanbankingnews.comSernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 DiabetesMay 14, 2025 | globenewswire.comSernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development PlansApril 17, 2025 | globenewswire.comSernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the MedApril 15, 2025 | globenewswire.comSernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 DiabetesApril 1, 2025 | globenewswire.comSernova names Pericles Calias as CDO and head of R&DMarch 11, 2025 | thepharmaletter.comSernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&DMarch 10, 2025 | globenewswire.comSernova Biotherapeutics Secures $1 Million Convertible Debt FinancingMarch 5, 2025 | globenewswire.comSernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with HypothyroidismMarch 3, 2025 | globenewswire.comSernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with HypothyroidismFebruary 3, 2025 | globenewswire.comSernova Corp. Shareholders Approve Key Resolutions at Annual MeetingJanuary 14, 2025 | tipranks.comSernova Advances Diabetes Cure with Strategic InitiativesJanuary 14, 2025 | tipranks.comSernova Financial joins FIA Tech’s Databank NetworkJanuary 13, 2025 | finextra.comSernova Announces Voting Results from its Annual and Special General Meeting of ShareholdersJanuary 13, 2025 | finance.yahoo.comSernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025December 20, 2024 | globenewswire.comFDA fast tracks type 1 diabetes cell therapy from VertexNovember 9, 2024 | pharmaphorum.comSernova to Present at the 2024 Cell & Gene Meeting on the MesaOctober 3, 2024 | finance.yahoo.comSernova Appoints David Paterson Ph.D. to Its Board of DirectorsSeptember 19, 2024 | finance.yahoo.comSernova Corp.September 6, 2024 | baystreet.caNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSEOVF, LXRX, RNAZ, and OMER Company DescriptionsLexicon Pharmaceuticals NASDAQ:LXRX$0.66 0.00 (-0.02%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.65 -0.01 (-1.05%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Omeros NASDAQ:OMER$3.16 -0.06 (-1.86%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.18 +0.02 (+0.66%) As of 05/23/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.TransCode Therapeutics NASDAQ:RNAZ$6.97 -0.65 (-8.53%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.30 +0.33 (+4.66%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.Sernova OTCMKTS:SEOVF$0.14 -0.01 (-8.48%) As of 05/23/2025 02:54 PM EasternSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
